T1	intervention 9 21	Capecitabine
T2	location 552 557	China
T3	eligibility 568 624	female patients with early TNBC after definitive surgery
T4	control 792 809	control treatment
T5	outcome-Measure 986 1013	disease-free survival (DFS)
T6	duration 1015 1050	Between June 2012 and December 2013
T7	No-of-participants 1052 1055	636
T8	No-of-participants 1094 1097	585
T9	control-participants 1144 1147	288
T10	intervention-participants 1163 1166	297
T11	duration 1190 1199	67 months
T12	outcome 1205 1220	5-year DFS rate
T13	intervention-value 1277 1282	86.3%
T15	outcome 1345 1377	Five-year overall survival rates
T16	intervention-value 1448 1453	93.3%
T17	control-value 1464 1469	90.7%
T18	outcome 1551 1579	grade â‰¥ 3 hand-foot syndrome
T19	outcome 1635 1646	neutropenia
T22	outcome 1701 1720	febrile neutropenia
T20	intervention-value 1662 1665	136
T25	intervention-value 1667 1672	45.8%
T21	control-value 1684 1687	118
T26	control-value 1689 1694	41.0%
T23	intervention-value 1736 1738	50
T27	intervention-value 1740 1745	16.8%
T24	control-value 1757 1759	46
T28	control-value 1761 1766	16.0%
T14	control-value 1285 1290	80.4%
